Abramson Cancer Center
Clinical Trials
431
Trial Phases
6 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (330 trials with phase data)• Click on a phase to view related trials
PUQS Sampling Study
- Conditions
- Cigarette SmokingTobacco UseCigarette Smoking Behavior
- First Posted Date
- 2025-09-30
- Last Posted Date
- 2025-09-30
- Lead Sponsor
- Abramson Cancer Center at Penn Medicine
- Target Recruit Count
- 472
- Registration Number
- NCT07199517
- Locations
- 🇺🇸
University of Pennsylvania, Philadelphia, Pennsylvania, United States
India HIV-CervCa Project
- Conditions
- HIV PositiveHIV NegativeCervical Cancer
- First Posted Date
- 2025-09-11
- Last Posted Date
- 2025-09-11
- Lead Sponsor
- Abramson Cancer Center at Penn Medicine
- Target Recruit Count
- 180
- Registration Number
- NCT07167069
- Locations
- 🇮🇳
Tata Memorial Hospital, Mumbai, Maharashtra, India
Short Course Radiotherapy
- Conditions
- Central Nervous System Cancer
- First Posted Date
- 2025-08-29
- Last Posted Date
- 2025-08-29
- Lead Sponsor
- Abramson Cancer Center at Penn Medicine
- Target Recruit Count
- 15
- Registration Number
- NCT07147179
- Locations
- 🇺🇸
University of Pennsylvania, Philadelphia, Pennsylvania, United States
Head Stabilization of Healthy Volunteers
- Conditions
- Healthy
- First Posted Date
- 2025-08-12
- Last Posted Date
- 2025-09-02
- Lead Sponsor
- Abramson Cancer Center at Penn Medicine
- Target Recruit Count
- 21
- Registration Number
- NCT07116759
- Locations
- 🇺🇸
University of Pennsylvania, Philadelphia, Pennsylvania, United States
FTT PET/CT in Pancreatic Neuroendocrine Tumors
- Conditions
- Neuroendocrine Carcinoma MetastaticPancreatic Tumors
- Interventions
- First Posted Date
- 2025-08-11
- Last Posted Date
- 2025-08-11
- Lead Sponsor
- Abramson Cancer Center at Penn Medicine
- Target Recruit Count
- 12
- Registration Number
- NCT07114939
- Locations
- 🇺🇸
University of Pennsylvania, Perelman Center for Advanced Medicine, Philadelphia, Pennsylvania, United States
- Prev
- 1
- 2
- 3
- 4
- 5
- 87
- Next
News
Viral Immunotherapy CAN-2409 Demonstrates 24.5-Month Median Survival in Checkpoint Inhibitor-Resistant NSCLC
A phase 2a trial of CAN-2409 viral immunotherapy showed median overall survival of 24.5 months in 46 patients with advanced NSCLC who failed immune checkpoint inhibitor therapy.
Repurposed Drugs Successfully Clear Dormant Breast Cancer Cells in Groundbreaking Clinical Trial
A first-of-its-kind clinical trial demonstrated that repurposed cancer drugs can effectively target dormant breast cancer cells, clearing them in 80% of participants and potentially preventing cancer recurrence.
Nivolumab Fails to Improve pCR Rate in Esophageal Adenocarcinoma: ECOG-ACRIN EA2174 Trial
The phase 2/3 ECOG-ACRIN EA2174 trial showed that adding nivolumab to neoadjuvant chemoradiation did not significantly improve pathologic complete response (pCR) rates in patients with locoregional esophageal adenocarcinoma.